Literature DB >> 23910792

Schizophrenia-like neurophysiological abnormalities in 22q11.2 deletion syndrome and their association to COMT and PRODH genotypes.

Omer Zarchi1, Miri Carmel, Chen Avni, Josef Attias, Amos Frisch, Elena Michaelovsky, Miriam Patya, Tamar Green, Ronnie Weinberger, Abraham Weizman, Doron Gothelf.   

Abstract

22q11.2 deletion syndrome (22q11.2DS) is a common genetic risk factor for the development of schizophrenia. We investigated two neurophysiological endophenotypes of schizophrenia - P50 sensory gating and mismatch negativity in 22q11.2DS subject and evaluated their association with catechol O-methyltransferase (COMT) and proline dehydrogenase (PRODH) genetic variants. We also assessed the association of neurophysiological measures with schizophrenia-like symptomatology in 22q11.2DS. Fifty-nine subjects, 41 with 22q11.2DS and 18 typically developing controls, participated in the study. The participants with 22q11.2DS were genotyped for the COMT Val(158)Met (rs4680) and PRODH Gln(19)Pro (rs2008720) and Arg(185)Trp (rs4819756) polymorphisms. Following psychiatric evaluation, all the participants underwent neurophysiological recordings and executive function assessment. The 22q11.2DS group showed poorer sensory gating of the P50 response than the controls. Within the 22q11.2DS group, the COMT Met allele was associated with poorer sensory gating, while both the COMT Met allele and the PRODH Pro-Arg haplotype were associated with smaller mismatch negativity amplitudes. Smaller mismatch negativity amplitudes predicted greater impairment of executive functions and greater severity of schizophrenia-like negative symptoms in 22q11.2DS. The current study demonstrates that sensory gating impairments that are typical of schizophrenia are found in 22q11.2DS subjects. Our results further suggest that COMT and PRODH genetic variations contribute to sensory gating and mismatch negativity schizophrenia-like impairments in 22q11.2DS, possibly via dopaminergic/glutamatergic networks. The associations of mismatch negativity impairments with increased severity of schizophrenia-like negative symptoms and poorer executive functions performance in our 22q11.2DS sample suggest that mismatch negativity is a potential endophenotype for schizophrenia in 22q11.2DS.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  22q11.2DS; Catechol O-methyltransferase; Endophenotype; Mismatch negativity; Proline dehydrogenase; Sensory gating

Mesh:

Substances:

Year:  2013        PMID: 23910792     DOI: 10.1016/j.jpsychires.2013.07.004

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  18 in total

1.  PRODH rs450046 and proline x COMT Val¹⁵⁸ Met interaction effects on intelligence and startle in adults with 22q11 deletion syndrome.

Authors:  Mariken B de Koning; Esther D A van Duin; Erik Boot; Oswald J N Bloemen; Jaap A Bakker; Kathryn M Abel; Thérèse A M J van Amelsvoort
Journal:  Psychopharmacology (Berl)       Date:  2015-06-12       Impact factor: 4.530

2.  The use of two different MLPA kits in 22q11.2 deletion syndrome.

Authors:  L J M Evers; J J M Engelen; L M H Houben; L M G Curfs; T A M J van Amelsvoort
Journal:  Eur J Med Genet       Date:  2016-02-24       Impact factor: 2.708

3.  Deletion size analysis of 1680 22q11.2DS subjects identifies a new recombination hotspot on chromosome 22q11.2.

Authors:  Tingwei Guo; Alexander Diacou; Hiroko Nomaru; Donna M McDonald-McGinn; Matthew Hestand; Wolfram Demaerel; Liangtian Zhang; Yingjie Zhao; Francisco Ujueta; Jidong Shan; Cristina Montagna; Deyou Zheng; Terrence B Crowley; Leila Kushan-Wells; Carrie E Bearden; Wendy R Kates; Doron Gothelf; Maude Schneider; Stephan Eliez; Jeroen Breckpot; Ann Swillen; Jacob Vorstman; Elaine Zackai; Felipe Benavides Gonzalez; Gabriela M Repetto; Beverly S Emanuel; Anne S Bassett; Joris R Vermeesch; Christian R Marshall; Bernice E Morrow
Journal:  Hum Mol Genet       Date:  2018-04-01       Impact factor: 6.150

4.  Cytosolic Accumulation of L-Proline Disrupts GABA-Ergic Transmission through GAD Blockade.

Authors:  Gregg W Crabtree; Alan J Park; Joshua A Gordon; Joseph A Gogos
Journal:  Cell Rep       Date:  2016-10-04       Impact factor: 9.423

5.  Discovery of the Membrane Binding Domain in Trifunctional Proline Utilization A.

Authors:  Shelbi L Christgen; Weidong Zhu; Nikhilesh Sanyal; Bushra Bibi; John J Tanner; Donald F Becker
Journal:  Biochemistry       Date:  2017-11-15       Impact factor: 3.162

6.  The Proline Cycle As a Potential Cancer Therapy Target.

Authors:  John J Tanner; Sarah-Maria Fendt; Donald F Becker
Journal:  Biochemistry       Date:  2018-04-23       Impact factor: 3.162

Review 7.  Molecular genetics of 22q11.2 deletion syndrome.

Authors:  Bernice E Morrow; Donna M McDonald-McGinn; Beverly S Emanuel; Joris R Vermeesch; Peter J Scambler
Journal:  Am J Med Genet A       Date:  2018-10       Impact factor: 2.802

8.  Association between prematurity and the evolution of psychotic disorders in 22q11.2 deletion syndrome.

Authors:  Yael Midbari Kufert; Ariela Nachmani; Einat Nativ; Abraham Weizman; Doron Gothelf
Journal:  J Neural Transm (Vienna)       Date:  2016-08-12       Impact factor: 3.575

Review 9.  22q11 deletion syndrome: a review of the neuropsychiatric features and their neurobiological basis.

Authors:  Chiara Squarcione; Maria Chiara Torti; Fabio Di Fabio; Massimo Biondi
Journal:  Neuropsychiatr Dis Treat       Date:  2013-12-04       Impact factor: 2.570

10.  Evidence that COMT genotype and proline interact on negative-symptom outcomes in schizophrenia and bipolar disorder.

Authors:  C L Clelland; V Drouet; K C Rilett; J A Smeed; R H Nadrich; A Rajparia; L L Read; J D Clelland
Journal:  Transl Psychiatry       Date:  2016-09-13       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.